相关实验视频
Updated: Jul 9, 2025

23:53
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
8.0K
在帕金森症中使用肉毒毒素治疗
Charenya Anandan1, Joseph Jankovic2
1Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX, United States of America; Neurology Care Line, Michael E DeBakey VA Medical Center, Houston, TX, United States of America.
Journal of the neurological sciences
|December 6, 2023
概括
毒素 (BoNT) 的治疗效益超出了FDA对运动障碍的最初批准. 专家经验表明,BoNT对各种与帕金森症相关的疾病有益,即使没有具体的FDA批准.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
背景情况:
- 毒素 (BoNT) 在1989年获得FDA批准,用于特定的神经和眼科疾病.
- 它的治疗应用已经远远超出了最初批准的适用范围.
- 本综述重点关注BoNT在管理与帕金森症相关的症状方面的不断发展的应用.
研究的目的:
- 提供关于毒素 (BoNT) 治疗应用的叙事综述.
- 探索BoNT在治疗, dystonia, sialorrhea 和膀功能障碍方面的疗效.
- 检查BoNT在管理勒沃多巴诱导的运动障碍和其他与帕金森症有关的问题的作用.
主要方法:
- 对现有文献和专家临床经验进行叙述性审查.
- 对各种用肉毒素治疗的疾病的治疗结果的分析.
- 专注于除了FDA批准的用途之外的指示.
主要成果:
- 玻丁毒素 (BoNT) 在治疗和 dystonia 方面表现出治疗效益.
- 有效治疗 (过度的唾液) 和膀自主症状.
- 在帕金森症患者中减轻勒沃多巴诱导的运动障碍方面显示出有前途.
结论:
- 毒素 (BoNT) 是帕金森症的一系列症状的有价值的治疗选择.
- 专家的临床经验支持其用于几个非标签性适应症.
- 进一步的研究和潜在的FDA批准可能会扩大其在神经系统疾病中的作用.
相关概念视频
Parkinson's Disease: Treatment
276
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
276
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
684
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
684
Parkinson's Disease: Overview
557
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
557
Skeletal Muscle Relaxants: Therapeutic Uses
488
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
488
Classification of Skeletal Muscle Relaxants
2.5K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
2.5K
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195

